2 Angebote ab € 73,20 €
- Gebundenes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
This definitive and comprehensive 2 volume text-reference book is essential reading for those who are primarily involved in the practice of nuclear medicine. Over 180 contributors, all of them internationally recognized authorities, focus on current and newly available radionuclide techniques and directly apply them to clinical practice. Covering all of the major body systems and organs in which nuclear medicine procedures are used, the book takes a disease oriented approach and this new edition features the latest advances in diagnostic and therapeutic modalities used in the detection and…mehr
Andere Kunden interessierten sich auch für
- Perspectives on Nuclear Medicine for Molecular Diagnosis and Integrated Therapy37,99 €
- Anisah el HelouAtlas of Diagnostic Nuclear Medicine74,99 €
- Brian J. McParlandNuclear Medicine Radiation Dosimetry111,99 €
- J. FitschenNuklearmedizin / Nuclear Medicine54,99 €
- Tapan K. GuptaRadiation, Ionization, and Detection in Nuclear Medicine147,99 €
- Radioactive Isotopes in Clinical Medicine and Research37,99 €
- Jeffrey C. Hoch (Hrsg.)Computational Aspects of the Study of Biological Macromolecules by Nuclear Magnetic Resonance Spectroscopy166,99 €
This definitive and comprehensive 2 volume text-reference book is essential reading for those who are primarily involved in the practice of nuclear medicine. Over 180 contributors, all of them internationally recognized authorities, focus on current and newly available radionuclide techniques and directly apply them to clinical practice. Covering all of the major body systems and organs in which nuclear medicine procedures are used, the book takes a disease oriented approach and this new edition features the latest advances in diagnostic and therapeutic modalities used in the detection and treatment of cancer, heart disease, neurologic disorders, trauma and other common and less common diseases. There are major revisions/ new chapters in the areas of brain imaging, movement disorders, stroke, lymphoma therapy, bone density, non-neurologic drug discovery, molecular imaging, cost/benefit analysis.
Produktdetails
- Produktdetails
- Verlag: Churchill Livingstone
- 3rd ed.
- Seitenzahl: 1950
- Englisch
- Gewicht: 7796g
- ISBN-13: 9780443073120
- ISBN-10: 0443073120
- Artikelnr.: 12731587
- Herstellerkennzeichnung Die Herstellerinformationen sind derzeit nicht verfügbar.
- Verlag: Churchill Livingstone
- 3rd ed.
- Seitenzahl: 1950
- Englisch
- Gewicht: 7796g
- ISBN-13: 9780443073120
- ISBN-10: 0443073120
- Artikelnr.: 12731587
- Herstellerkennzeichnung Die Herstellerinformationen sind derzeit nicht verfügbar.
Peter J. Ell, MD, MSc, PhD, FRCR, FRCP, Professor of Nuclear Medicine, University College London, London, UK
Sam Gambhir, MD, PhD , Director, Molecular Imaging Program at Stanford (MIPS); Professor of Radiology and Bio-X Program; Chief, Division of Nuclear Medicine, Stanford University School of Medicine, Stanford, CA, USA
Sam Gambhir, MD, PhD , Director, Molecular Imaging Program at Stanford (MIPS); Professor of Radiology and Bio-X Program; Chief, Division of Nuclear Medicine, Stanford University School of Medicine, Stanford, CA, USA
Section 1: Nuclear medicine in tumor diagnosis and therapy
Part A: Diagnosis
1. Tumor-seeking radiopharmaceuticals: nature and mechanisms
2 Radionuclide imaging of hepatic tumors
3 PET in lymphoma and malignant melanoma
4 Parathyroid imaging
5 Adrenocortical scintigraphy
6 Gallium scintigraphy in tumor diagnosis and management
7 Thallium-201 chloride: a tumor imaging agent
8 MIBG in the diagnosis of neuroendocrine tumors
9 Peptide receptor scintigraphy in oncology
10 The diagnostic role of radiolabeled antibodies in cancer
11 Cancer cell biology basis for nuclear oncology
12 Differentiated thyroid carcinoma
13 Medullary thyroid cancer
14 Breast scintigraphy
15 Pediatric tumors
16 Functional analysis of cancer therapy effects in other organs
17 The use of intraoperative probes in surgical oncology
18 The sentinel lymph node in surgical oncology
19 FDG PET Imaging of Head and Neck Cancer
20 External Beam Radiotherapy Treatment Planning with PET
21 PET in aerodigestive tumors
22 PET in gynecological tumors (breast, cervical and ovarian)
23 Nuclear medicine imaging in pediatric oncology
24 Positron Emission Tomography (PET) in genitourinary tumors: prostate, bladder, testicular and renal cancer
25 Future clinical applications of PET (amino acid and nucleoside imaging)
26 PET imaging of brain tumors
Section 1: Nuclear medicine in tumor diagnosis and therapy
Part B: Radionuclide therapy
27 Principles of radionuclide therapy
28 Dosimetric and radiobiological considerations: The MIRD concept
29 Dosimetric and radiobiological considerations: Patient-individual dosimetry
30 Radioiodine therapy of the thyroid: Treatment of benign thyroid diseases
31 Radioiodine therapy of the thyroid: Treatment of thyroid malignancies
32 Phosphorus-32 therapy in myeloproliferative disorders
33 Palliation of bone pain
34 Radioimmunotherapy of hematologic neoplasms
35 Radioimmunotherapy of solid tumors
36 MIBG therapy
37 Receptor-targeted radiopeptide therapy
38 Use of radiolipiodol in the treatment of hepatic tumours
39 Alternative approaches to targeting therapy
40 New developments: Nuclear gene therapy
41 Atlas 1: PET and PET/CT
42 Atlas 2: SPET and SPET/CT
Section 2: Nuclear medicine in disorders of bones and joints
43 Bone scintigraphy: the procedure and interpretation
44 Evaluation of primary bone tumors
45 The evaluation of malignancy: metastatic bone disease
46 Assessment of infection
47 Radionuclide assessment of the painful joint prosthesis
48 Vascular manifestations
49 Bone scintigraphy in trauma
50 Bone scintigraphy in sports medicine
51 Growth and metabolic disorders
52 Arthritis: current status of scintigraphy and future trends
53 Radiation synovectomy
Section 3: Quantitative studies of gastrointestinal function
54 Salivary gland disorders
55 Esophageal function (transport and motility)
56 Gastric motility
57 Intestines: evaluation of absorption
58 Studies of small bowel and colonic transit
59 Hepatobiliary function: biliary kinetics
60 Scintigraphic measurement of hepatic function
Section 4: Nuclear medicine in acute care
61 Nuclear cardiology and cardiac transplantation
62 Cardiovascular conditions: venous thrombosis
63 Pulmonary embolism
64 Non-embolic disease of the lungs
65 Gastrointestinal bleeding
66 Cholescintigraphy
67 Neonatal hyperbilirubinemia
68 Nuclear medicine in acute care of neurological patients
69 Radiolabeled agents for the localization of infection and inflammation
70 Undiagnosed fever
71 Inflammatory bowel disease
72 Nuclear imaging in cardiovascular infection and cardiac transplant rejection
73 The immunocompromised patient
Section 5: Nuclear cardiology
74 Radiopharmaceuticals for the study of the heart
75 Radionuclide ventriculography and the assessment of impaired ventricula
Part A: Diagnosis
1. Tumor-seeking radiopharmaceuticals: nature and mechanisms
2 Radionuclide imaging of hepatic tumors
3 PET in lymphoma and malignant melanoma
4 Parathyroid imaging
5 Adrenocortical scintigraphy
6 Gallium scintigraphy in tumor diagnosis and management
7 Thallium-201 chloride: a tumor imaging agent
8 MIBG in the diagnosis of neuroendocrine tumors
9 Peptide receptor scintigraphy in oncology
10 The diagnostic role of radiolabeled antibodies in cancer
11 Cancer cell biology basis for nuclear oncology
12 Differentiated thyroid carcinoma
13 Medullary thyroid cancer
14 Breast scintigraphy
15 Pediatric tumors
16 Functional analysis of cancer therapy effects in other organs
17 The use of intraoperative probes in surgical oncology
18 The sentinel lymph node in surgical oncology
19 FDG PET Imaging of Head and Neck Cancer
20 External Beam Radiotherapy Treatment Planning with PET
21 PET in aerodigestive tumors
22 PET in gynecological tumors (breast, cervical and ovarian)
23 Nuclear medicine imaging in pediatric oncology
24 Positron Emission Tomography (PET) in genitourinary tumors: prostate, bladder, testicular and renal cancer
25 Future clinical applications of PET (amino acid and nucleoside imaging)
26 PET imaging of brain tumors
Section 1: Nuclear medicine in tumor diagnosis and therapy
Part B: Radionuclide therapy
27 Principles of radionuclide therapy
28 Dosimetric and radiobiological considerations: The MIRD concept
29 Dosimetric and radiobiological considerations: Patient-individual dosimetry
30 Radioiodine therapy of the thyroid: Treatment of benign thyroid diseases
31 Radioiodine therapy of the thyroid: Treatment of thyroid malignancies
32 Phosphorus-32 therapy in myeloproliferative disorders
33 Palliation of bone pain
34 Radioimmunotherapy of hematologic neoplasms
35 Radioimmunotherapy of solid tumors
36 MIBG therapy
37 Receptor-targeted radiopeptide therapy
38 Use of radiolipiodol in the treatment of hepatic tumours
39 Alternative approaches to targeting therapy
40 New developments: Nuclear gene therapy
41 Atlas 1: PET and PET/CT
42 Atlas 2: SPET and SPET/CT
Section 2: Nuclear medicine in disorders of bones and joints
43 Bone scintigraphy: the procedure and interpretation
44 Evaluation of primary bone tumors
45 The evaluation of malignancy: metastatic bone disease
46 Assessment of infection
47 Radionuclide assessment of the painful joint prosthesis
48 Vascular manifestations
49 Bone scintigraphy in trauma
50 Bone scintigraphy in sports medicine
51 Growth and metabolic disorders
52 Arthritis: current status of scintigraphy and future trends
53 Radiation synovectomy
Section 3: Quantitative studies of gastrointestinal function
54 Salivary gland disorders
55 Esophageal function (transport and motility)
56 Gastric motility
57 Intestines: evaluation of absorption
58 Studies of small bowel and colonic transit
59 Hepatobiliary function: biliary kinetics
60 Scintigraphic measurement of hepatic function
Section 4: Nuclear medicine in acute care
61 Nuclear cardiology and cardiac transplantation
62 Cardiovascular conditions: venous thrombosis
63 Pulmonary embolism
64 Non-embolic disease of the lungs
65 Gastrointestinal bleeding
66 Cholescintigraphy
67 Neonatal hyperbilirubinemia
68 Nuclear medicine in acute care of neurological patients
69 Radiolabeled agents for the localization of infection and inflammation
70 Undiagnosed fever
71 Inflammatory bowel disease
72 Nuclear imaging in cardiovascular infection and cardiac transplant rejection
73 The immunocompromised patient
Section 5: Nuclear cardiology
74 Radiopharmaceuticals for the study of the heart
75 Radionuclide ventriculography and the assessment of impaired ventricula
Section 1: Nuclear medicine in tumor diagnosis and therapy
Part A: Diagnosis
1. Tumor-seeking radiopharmaceuticals: nature and mechanisms
2 Radionuclide imaging of hepatic tumors
3 PET in lymphoma and malignant melanoma
4 Parathyroid imaging
5 Adrenocortical scintigraphy
6 Gallium scintigraphy in tumor diagnosis and management
7 Thallium-201 chloride: a tumor imaging agent
8 MIBG in the diagnosis of neuroendocrine tumors
9 Peptide receptor scintigraphy in oncology
10 The diagnostic role of radiolabeled antibodies in cancer
11 Cancer cell biology basis for nuclear oncology
12 Differentiated thyroid carcinoma
13 Medullary thyroid cancer
14 Breast scintigraphy
15 Pediatric tumors
16 Functional analysis of cancer therapy effects in other organs
17 The use of intraoperative probes in surgical oncology
18 The sentinel lymph node in surgical oncology
19 FDG PET Imaging of Head and Neck Cancer
20 External Beam Radiotherapy Treatment Planning with PET
21 PET in aerodigestive tumors
22 PET in gynecological tumors (breast, cervical and ovarian)
23 Nuclear medicine imaging in pediatric oncology
24 Positron Emission Tomography (PET) in genitourinary tumors: prostate, bladder, testicular and renal cancer
25 Future clinical applications of PET (amino acid and nucleoside imaging)
26 PET imaging of brain tumors
Section 1: Nuclear medicine in tumor diagnosis and therapy
Part B: Radionuclide therapy
27 Principles of radionuclide therapy
28 Dosimetric and radiobiological considerations: The MIRD concept
29 Dosimetric and radiobiological considerations: Patient-individual dosimetry
30 Radioiodine therapy of the thyroid: Treatment of benign thyroid diseases
31 Radioiodine therapy of the thyroid: Treatment of thyroid malignancies
32 Phosphorus-32 therapy in myeloproliferative disorders
33 Palliation of bone pain
34 Radioimmunotherapy of hematologic neoplasms
35 Radioimmunotherapy of solid tumors
36 MIBG therapy
37 Receptor-targeted radiopeptide therapy
38 Use of radiolipiodol in the treatment of hepatic tumours
39 Alternative approaches to targeting therapy
40 New developments: Nuclear gene therapy
41 Atlas 1: PET and PET/CT
42 Atlas 2: SPET and SPET/CT
Section 2: Nuclear medicine in disorders of bones and joints
43 Bone scintigraphy: the procedure and interpretation
44 Evaluation of primary bone tumors
45 The evaluation of malignancy: metastatic bone disease
46 Assessment of infection
47 Radionuclide assessment of the painful joint prosthesis
48 Vascular manifestations
49 Bone scintigraphy in trauma
50 Bone scintigraphy in sports medicine
51 Growth and metabolic disorders
52 Arthritis: current status of scintigraphy and future trends
53 Radiation synovectomy
Section 3: Quantitative studies of gastrointestinal function
54 Salivary gland disorders
55 Esophageal function (transport and motility)
56 Gastric motility
57 Intestines: evaluation of absorption
58 Studies of small bowel and colonic transit
59 Hepatobiliary function: biliary kinetics
60 Scintigraphic measurement of hepatic function
Section 4: Nuclear medicine in acute care
61 Nuclear cardiology and cardiac transplantation
62 Cardiovascular conditions: venous thrombosis
63 Pulmonary embolism
64 Non-embolic disease of the lungs
65 Gastrointestinal bleeding
66 Cholescintigraphy
67 Neonatal hyperbilirubinemia
68 Nuclear medicine in acute care of neurological patients
69 Radiolabeled agents for the localization of infection and inflammation
70 Undiagnosed fever
71 Inflammatory bowel disease
72 Nuclear imaging in cardiovascular infection and cardiac transplant rejection
73 The immunocompromised patient
Section 5: Nuclear cardiology
74 Radiopharmaceuticals for the study of the heart
75 Radionuclide ventriculography and the assessment of impaired ventricula
Part A: Diagnosis
1. Tumor-seeking radiopharmaceuticals: nature and mechanisms
2 Radionuclide imaging of hepatic tumors
3 PET in lymphoma and malignant melanoma
4 Parathyroid imaging
5 Adrenocortical scintigraphy
6 Gallium scintigraphy in tumor diagnosis and management
7 Thallium-201 chloride: a tumor imaging agent
8 MIBG in the diagnosis of neuroendocrine tumors
9 Peptide receptor scintigraphy in oncology
10 The diagnostic role of radiolabeled antibodies in cancer
11 Cancer cell biology basis for nuclear oncology
12 Differentiated thyroid carcinoma
13 Medullary thyroid cancer
14 Breast scintigraphy
15 Pediatric tumors
16 Functional analysis of cancer therapy effects in other organs
17 The use of intraoperative probes in surgical oncology
18 The sentinel lymph node in surgical oncology
19 FDG PET Imaging of Head and Neck Cancer
20 External Beam Radiotherapy Treatment Planning with PET
21 PET in aerodigestive tumors
22 PET in gynecological tumors (breast, cervical and ovarian)
23 Nuclear medicine imaging in pediatric oncology
24 Positron Emission Tomography (PET) in genitourinary tumors: prostate, bladder, testicular and renal cancer
25 Future clinical applications of PET (amino acid and nucleoside imaging)
26 PET imaging of brain tumors
Section 1: Nuclear medicine in tumor diagnosis and therapy
Part B: Radionuclide therapy
27 Principles of radionuclide therapy
28 Dosimetric and radiobiological considerations: The MIRD concept
29 Dosimetric and radiobiological considerations: Patient-individual dosimetry
30 Radioiodine therapy of the thyroid: Treatment of benign thyroid diseases
31 Radioiodine therapy of the thyroid: Treatment of thyroid malignancies
32 Phosphorus-32 therapy in myeloproliferative disorders
33 Palliation of bone pain
34 Radioimmunotherapy of hematologic neoplasms
35 Radioimmunotherapy of solid tumors
36 MIBG therapy
37 Receptor-targeted radiopeptide therapy
38 Use of radiolipiodol in the treatment of hepatic tumours
39 Alternative approaches to targeting therapy
40 New developments: Nuclear gene therapy
41 Atlas 1: PET and PET/CT
42 Atlas 2: SPET and SPET/CT
Section 2: Nuclear medicine in disorders of bones and joints
43 Bone scintigraphy: the procedure and interpretation
44 Evaluation of primary bone tumors
45 The evaluation of malignancy: metastatic bone disease
46 Assessment of infection
47 Radionuclide assessment of the painful joint prosthesis
48 Vascular manifestations
49 Bone scintigraphy in trauma
50 Bone scintigraphy in sports medicine
51 Growth and metabolic disorders
52 Arthritis: current status of scintigraphy and future trends
53 Radiation synovectomy
Section 3: Quantitative studies of gastrointestinal function
54 Salivary gland disorders
55 Esophageal function (transport and motility)
56 Gastric motility
57 Intestines: evaluation of absorption
58 Studies of small bowel and colonic transit
59 Hepatobiliary function: biliary kinetics
60 Scintigraphic measurement of hepatic function
Section 4: Nuclear medicine in acute care
61 Nuclear cardiology and cardiac transplantation
62 Cardiovascular conditions: venous thrombosis
63 Pulmonary embolism
64 Non-embolic disease of the lungs
65 Gastrointestinal bleeding
66 Cholescintigraphy
67 Neonatal hyperbilirubinemia
68 Nuclear medicine in acute care of neurological patients
69 Radiolabeled agents for the localization of infection and inflammation
70 Undiagnosed fever
71 Inflammatory bowel disease
72 Nuclear imaging in cardiovascular infection and cardiac transplant rejection
73 The immunocompromised patient
Section 5: Nuclear cardiology
74 Radiopharmaceuticals for the study of the heart
75 Radionuclide ventriculography and the assessment of impaired ventricula